Stock 002099 ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhejiang Hisoar Pharmaceutical Co., Ltd.

Equities

002099

CNE000001PY2

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-05-07 EDT 		5-day change 1st Jan Change
6.48 CNY -1.22% Intraday chart for Zhejiang Hisoar Pharmaceutical Co., Ltd. +2.21% -9.87%
04-28 Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-18 Hisoar Pharma's Unit Passes German Health Regulator's Inspection MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 7,317 11,525 13,759 13,338 11,347 11,639
Enterprise Value (EV) 1 5,811 10,169 12,220 12,094 10,858 11,273
P/E ratio 11.9 x 14.8 x 42.5 x 137 x 140 x -27.7 x
Yield 6.38% 4.21% 0.24% 1.21% 0.71% -
Capitalization / Revenue 2.69 x 3.92 x 5.57 x 5.37 x 4.2 x 5.36 x
EV / Revenue 2.14 x 3.46 x 4.94 x 4.87 x 4.02 x 5.19 x
EV / EBITDA 6.79 x 9.47 x 18 x 29.8 x 25.9 x 122 x
EV / FCF 15 x 16.5 x 16.9 x 30.1 x 152 x 55.6 x
FCF Yield 6.69% 6.06% 5.92% 3.32% 0.66% 1.8%
Price to Book 1.36 x 2.01 x 2.35 x 2.18 x 1.86 x 2.08 x
Nbr of stocks (in thousands) 1,618,820 1,618,715 1,618,715 1,618,715 1,618,715 1,618,715
Reference price 2 4.520 7.120 8.500 8.240 7.010 7.190
Announcement Date 19-02-17 20-01-22 21-04-28 22-04-22 23-04-24 24-04-28
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,719 2,941 2,471 2,485 2,704 2,172
EBITDA 1 855.5 1,074 678.6 406.2 420 92.48
EBIT 1 663.3 870.8 422.1 117.2 88.57 -267.5
Operating Margin 24.4% 29.6% 17.08% 4.72% 3.28% -12.32%
Earnings before Tax (EBT) 1 697.3 912.5 393.5 123 100.8 -466.2
Net income 1 605 770.8 319.7 95.23 88.01 -420.1
Net margin 22.25% 26.2% 12.94% 3.83% 3.25% -19.34%
EPS 2 0.3800 0.4800 0.2000 0.0600 0.0500 -0.2600
Free Cash Flow 1 388.7 616.7 723.9 401.5 71.41 202.8
FCF margin 14.3% 20.97% 29.29% 16.16% 2.64% 9.34%
FCF Conversion (EBITDA) 45.43% 57.43% 106.68% 98.82% 17% 219.27%
FCF Conversion (Net income) 64.24% 80.01% 226.41% 421.58% 81.13% -
Dividend per Share 2 0.2883 0.3000 0.0200 0.1000 0.0500 -
Announcement Date 19-02-17 20-01-22 21-04-28 22-04-22 23-04-24 24-04-28
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,506 1,356 1,539 1,244 489 366
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 389 617 724 401 71.4 203
ROE (net income / shareholders' equity) 11.5% 13.9% 5.52% 1.57% 1.41% -7.2%
ROA (Net income/ Total Assets) 5.72% 7.9% 3.79% 0.96% 0.67% -2.1%
Assets 1 10,582 9,760 8,439 9,882 13,049 19,993
Book Value Per Share 2 3.330 3.540 3.620 3.780 3.770 3.460
Cash Flow per Share 2 1.210 0.9600 1.220 1.130 0.9200 0.8800
Capex 1 256 161 74.2 230 179 153
Capex / Sales 9.41% 5.46% 3% 9.24% 6.64% 7.05%
Announcement Date 19-02-17 20-01-22 21-04-28 22-04-22 23-04-24 24-04-28
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD. Stock Zhejiang Hisoar Pharmaceutical Co., Ltd.
-9.87% 1.43B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.95% 698B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.97% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.83% 328B
ABBVIE INC. Stock AbbVie Inc.
+3.54% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.70% 238B
NOVARTIS AG Stock Novartis AG
+6.68% 203B
ROCHE HOLDING AG Stock Roche Holding AG
-9.08% 198B
AMGEN INC. Stock Amgen Inc.
+6.70% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002099 Stock
  4. Financials Zhejiang Hisoar Pharmaceutical Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW